Revive Therapeutics Ltd (RVVTF)
$0.19 0.00 (2.00%)
13:22 EDT RVVTF Stock Quote Delayed 30 Minutes
Previous Close $0.19
Market Cap 4.75M
PE Ratio -
Volume (Avg. Vol.) 958,974
Day's Range 0.18 - 0.20
52-Week Range 0.02 - 0.50
Dividend & Yield N/A (N/A)
RVVTF Stock Predictions, Articles, and Revive Therapeutics Ltd News
- From InvestorPlace
- From the Web
By Joel Baglole
Some cheap stocks deserve to be cheap, but others are simply waiting to rocket higher. My list includes some of the best penny stocks now.
Psychedelics are losing their negative stigma, and the Shroom Boom is coming. To play that boom, consider these psychedelic stocks to buy.
If you’ve got the iron stomach for volatility, these seven penny stocks could provide astounding gains amid the turmoil.
From Seeking Alpha
Revive Therapeutics' (OTCPK:RVVTF) expanded access protocol (EAP) for compassionate use of Bucillamine in the treatment of COVID-19 received approval from the independent Institutional Review Board (IRB).The EAP is being done to complement the Company’s Phase 3 COVID-19 study in the U.S. Revive expects patient enrollment in U.S. this month.The objective is to monitor the safety and efficacy of Bucillamine (600 mg/day) and any clinical symptoms when administered up to 14 days in hospitalized patients with severe COVID-19.
Revive Therapeutics nabs option for rights to psilocybin treatment for methamphetamine addiction (OTCMKTS:RVVTF)
From Seeking Alpha
Revive Therapeutics (OTCPK:RVVTF +1.9%) inks a Clinical Trial Agreement with the Board of Regents of the University of Wisconsin System (UWS) to conduct a study with researchers at the University of Wisconsin-Madison evaluating psilocybin, a psychedelic compound produced in certain mushrooms, for the potential treatment of adults with methamphetamine use disorder.Under the terms of the contract, the company has the option to exclusively in-license all rights, title and interest that UWS may have or obtain in any invention that results from the clinical study.